Evotec AG (NASDAQ:EVO) Short Interest Update

Evotec AG (NASDAQ:EVO) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 47,630 shares, a growth of 68.6% from the July 15th total of 28,249 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 48,877 shares, the short-interest ratio is presently 1.0 days.

Analysts Set New Price Targets

EVO has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Evotec in a report on Tuesday, July 21st. Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. HC Wainwright dropped their target price on Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, July 15th. Wall Street Zen lowered Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

Evotec Trading Down 3.1%

Shares of EVO stock traded down $0.06 during trading hours on Tuesday, hitting $1.90. 10,363 shares of the company’s stock traded hands, compared to its average volume of 96,892. The stock’s 50 day simple moving average is $2.36 and its 200 day simple moving average is $2.79. Evotec has a 12 month low of $1.89 and a 12 month high of $4.27. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Apollon Wealth Management LLC acquired a new position in Evotec during the 1st quarter worth about $28,000. BNP Paribas Financial Markets increased its stake in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares during the period. Bank of America Corp DE increased its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the period. Marshall Wace LLP bought a new position in shares of Evotec during the fourth quarter worth about $40,000. Finally, XTX Topco Ltd bought a new position in shares of Evotec during the second quarter worth about $66,000. 5.81% of the stock is owned by institutional investors.

More Evotec News

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $4.00 price target for Evotec. The target implies significant upside and suggests the analyst believes the company’s longer-term pipeline and recovery prospects remain intact. HC Wainwright Weighs in on Evotec’s Q1 Earnings
• Neutral Sentiment: HC Wainwright still projects Evotec could return to profitability over the longer term, forecasting positive EPS of $0.21 in FY2029 and $0.28 in FY2030, despite reducing both estimates.
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS forecasts to a loss of $0.14 per share from previous estimates of losses of $0.04 and $0.02, respectively. The revisions indicate weaker near-term earnings expectations.
• Negative Sentiment: The analyst reduced its FY2026 EPS forecast to a loss of $0.83 from a loss of $0.31, while lowering FY2029 EPS to $0.21 from $0.33 and FY2030 EPS to $0.28 from $0.48. These cuts point to a slower-than-expected path toward profitability and are likely contributing to the stock’s decline.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.